SCHEMBL716928

SCHEMBL716928

CCOC(=O)CCN(C)C(=O)c1ccc(NC(c2sc3ncccc3c2C)C2CCCCC2)cc1

nearest known ligand 0.38

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.38
CYP1A2 P05177 1/20 0.38
MAPT P10636 1/20 0.38
CYP2C9 P11712 1/20 0.38
HPGD P15428 1/20 0.38
CYP2C19 P33261 1/20 0.38
RAB9A P51151 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
RCE1 Q9Y256 1/20 0.37
KDM4E B2RXH2 2/20 0.35
NAMPT P43490 2/20 0.34
PDE7A Q13946 1/20 0.33
HDAC6 Q9UBN7 4/20 0.33
ITK Q08881 1/20 0.33
OPRK1 P41145 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
TSHR P16473 2/20 0.32
IDH1 O75874 1/20 0.32
NQO2 P16083 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL721611 0.98 RCE1 (0.37) NPC1CYP1A2MAPTCYP2C9HPGD
SCHEMBL716440 0.91 RCE1 (0.41) NPC1CYP1A2MAPTCYP2C9HPGD
SCHEMBL719238 0.89 RCE1 (0.41) NPC1MAPTRCE1KDM4ENAMPT
SCHEMBL717719 0.87 TP53 (0.36) MAPTSMN1; SMN2NAMPTHDAC6L3MBTL1
SCHEMBL722172 0.87 RCE1 (0.41) NPC1MAPTRCE1KDM4ENAMPT
SCHEMBL718103 0.86 MEN1 (0.41) NPC1CYP1A2MAPTCYP2C9HPGD
SCHEMBL3401014 0.85 NAMPT (0.34) CYP1A2MAPTCYP2C9HPGDCYP2C19
SCHEMBL718563 0.85 NAMPT (0.34) CYP1A2MAPTCYP2C9HPGDCYP2C19
SCHEMBL720850 0.85 GCGR (0.36) MAPTSMN1; SMN2NAMPTHDAC6L3MBTL1
SCHEMBL721279 0.83 NAMPT (0.33) MAPTRCE1NAMPTPDE7AL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8436043-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-05-07 US disclosed
US-20120270865-A2 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-10-25 US disclosed
US-20120053173-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-03-01 US disclosed
EP-2251326-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2010-11-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053173-A1 HETEROCYCLIC COMPOUND SLC5A2, SLC5A1, IAPP NPC1 902/4885CYP1A2 774/4885MAPT 4533/4885
US-20120270865-A2 HETEROCYCLIC COMPOUND SLC5A2, SLC5A1, IAPP NPC1 902/4885CYP1A2 774/4885MAPT 4533/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.